Hypertension
📧 Sign up to get email alerts when something new happens for Hypertension.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2023-03-20Clinical Trial Update: Effect of PRM-125 on Ambulatory Blood Pressure [Phase 3]
Phase 3 trial evaluating PRM-125 for ambulatory blood pressure was withdrawn.
-
CLINICAL_TRIALS trial_result · 2023-03-20Clinical Trial Update: Assessing the Feasibility of N-of-1 Trials in Children With Hypertension and Chronic Kidney Disease [NA]
A completed clinical trial exploring the feasibility of N-of-1 trials in pediatric patients with hypertension and chronic kidney disease.
-
FDA approval · 2023-03-17FDA Approved: HYZAAR — Supplemental Application (Organon LLC)
FDA approved a supplemental application for HYZAAR (losartan potassium and hydrochlorothiazide) from Organon LLC. The approval pertains to c…
-
FDA approval · 2023-03-17FDA Approved: LISINOPRIL AND HYDROCHLOROTHIAZIDE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
FDA approved a supplemental application for the Lisinopril and Hydrochlorothiazide combination from Lupin Pharmaceuticals, formalizing an ap…
-
FDA approval · 2023-03-16FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
The FDA approved a supplemental application for Hydrochlorothiazide submitted by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals In…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2023-03-16Clinical Trial Update: Strengthening Referral Networks for Management of Hypertension Across the Health System (STRENGTHS) [Phase 3]
A Phase 3 clinical trial updating referral networks to improve management of hypertension within a health system.
-
FDA approval · 2023-03-15FDA Approved: AMLODIPINE AND BENAZEPRIL HYDROCHLORIDE — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for a fixed-dose combination of amlodipine and benazepril hydrochloride manufactured by Rising Pharm…
-
FDA label_change · 2023-03-15FDA Approved: IRBESARTAN — Supplemental Application (Solco Healthcare U.S., LLC)
FDA approved a supplemental application for IRBESARTAN from Solco Healthcare U.S., LLC, indicating a labeling change for the product.
-
CLINICAL_TRIALS withdrawal · 2023-03-15Clinical Trial Update: Neural Mechanism of Aldosterone-induced Insulin Resistance [Phase 4]
A Phase 4 clinical trial investigating neural mechanisms of aldosterone-induced insulin resistance has been withdrawn.
-
FDA approval · 2023-03-10FDA Approved: TOPROL XL — Supplemental Application (Melinta Therapeutics, LLC)
The FDA approved a supplemental application for Toprol XL (metoprolol succinate) submitted by Melinta Therapeutics, LLC.
-
FDA approval · 2023-03-10FDA Approved: TELMISARTAN — Supplemental Application (Solco Healthcare US, LLC)
FDA approved a supplemental application for telmisartan submitted by Solco Healthcare US, LLC.
-
FDA approval · 2023-03-07FDA Approved: DILTIAZEM HYDROCHLORIDE — Original Application (Slate Run Pharmaceuticals, LLC)
FDA approved Slate Run Pharmaceuticals, LLC's generic diltiazem hydrochloride through an original ANDA.
-
FDA approval · 2023-03-06FDA Approved: PRAZOSIN HYDROCHLORIDE — Original Application (Alembic Pharmaceuticals Limited)
FDA approves Alembic Pharmaceuticals Limited's original application for prazosin hydrochloride, making a generic prazosin hydrochloride prod…
-
FDA approval · 2023-03-01FDA Approved: OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental ANDA for a generic fixed-dose combination of olmesartan medoxomil, amlodipine, and hydrochlorothiazide for hyper…
-
FDA approval · 2023-03-01FDA Approved: OLMESARTAN MEDOXOMIL — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved Glenmark Pharmaceuticals Inc., USA's supplemental application for olmesartan medoxomil (ANDA 203281), a generic antihyperte…
-
FDA approval · 2023-03-01FDA Approved: DILTIAZEM HYDROCHLORIDE — Original Application (Upsher-Smith Laboratories, LLC)
FDA approved Upsher-Smith's generic diltiazem hydrochloride (Original Application) as a generic version of diltiazem hydrochloride.
-
CLINICAL_TRIALS trial_result · 2023-02-28Clinical Trial Update: Safety and Efficacy Study of Clevidipine to Control Hypertension in Patients Admitted With Aneurysmal Subarachnoid Hemorrhage [Phase 2]
Phase 2 clinical trial assessing safety and efficacy of clevidipine to control hypertension in patients with aneurysmal subarachnoid hemorrh…
-
FDA approval · 2023-02-27FDA Approved: METOPROLOL SUCCINATE — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for metoprolol succinate from Actavis Pharma, Inc., authorizing a generic extended-release metoprolo…
-
FDA approval · 2023-02-23FDA Approved: IRBESARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Solco Healthcare US, LLC)
FDA approved a supplemental application for the generic irbesartan and hydrochlorothiazide from Solco Healthcare US, LLC, to maintain/expand…
-
FDA approval · 2023-02-23FDA Approved: LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE — Supplemental Application (Solco Healthcare US, LLC)
FDA approved a supplemental application for the generic Losartan Potassium and Hydrochlorothiazide from Solco Healthcare US, LLC.
-
FDA approval · 2023-02-23FDA Approved: LOSARTAN POTASSIUM — Original Application (Granules Pharmaceuticals Inc.)
FDA approved Granules Pharmaceuticals Inc.'s original ANDA for Losartan Potassium tablets, authorizing a generic version of losartan potassi…
-
CLINICAL_TRIALS trial_result · 2023-02-21Clinical Trial Update: Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan [Phase 2]
Phase 2 trial comparing different doses of rostafuroxin to losartan for antihypertensive effects has completed.
-
CLINICAL_TRIALS withdrawal · 2023-02-21Clinical Trial Update: Effect of Eplerenone on Novel Biomarkers of Mineralocorticoid Receptor Activation (ENOVA) [Phase 4]
A Phase 4 trial evaluating the effect of eplerenone on novel biomarkers of mineralocorticoid receptor activation has been withdrawn.
-
FDA approval · 2023-02-17FDA Approved: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for the generic Spironolactone and Hydrochlorothiazide from Mylan Pharmaceuticals Inc., a combinatio…
-
CLINICAL_TRIALS trial_result · 2023-02-14Clinical Trial Update: ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD) [Phase 4]
Phase 4 trial comparing ACE inhibitor/ calcium channel blocker versus ACE inhibitor/ diuretic combination antihypertensive therapy in Chines…